Together Against Bacterial Infections
Vienna - Intercell AG has signed a license agreement with the pharmaceutical company Merck & Co., Inc. for the development of certain bacterial vaccines and an option to develop antibody products. As a result of this extended agreement, Intercell will receive upfront-, license-, and milestone-payments for a vaccine product. If Merck exercises the option for an antibody product, the Vienna-based company will obtain additional payments and royalty payments on product sales. Merck receives exclusive worldwide rights to commercialize any products that may be developed under the agreement. Further financial details were not disclosed.
This license agreement is the continuation of a research collaboration with Merck that began three years ago. During this collaboration, Intercell applied its Antigen Identification Program (AIP) to identify relevant antigens directed towards a specific bacterial target.